Identification of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam from ST11 Carbapenem-Resistant Klebsiella pneumoniae Strains

Yuchen Wu,a Xuemei Yang,b Congcong Liu,a Yanyan Zhang,a Yan Chu Cheung,b Edward Wai Chi Chan,c Sheng Chen,b Rong Zhang

aDepartment of Clinical Laboratory, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
bDepartment of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Kowloon, Hong Kong
cState Key Lab of Chemical Biology and Drug Discovery, Department of Applied Biology and Chemical Technology, Hong Kong Polytechnic University, Hung Hom, Hong Kong

Yuchen Wu and Xuemei Yang contributed equally to this article. Author order was determined by the corresponding authors after negotiation.

ABSTRACT A novel Klebsiella pneumoniae carbapenemase (KPC) variant, KPC-93, was identified in two Klebsiella pneumoniae clinical isolates from a patient from China treated with ceftazidime-avibactam. KPC-93 possessed a five-amino-acids insertion (Pro-Asn-Asn-Arg-Ala) between Ambler positions 267 and 268 in KPC-2. Cloning and expression of the blaKPC-93 gene in Escherichia coli, followed by determination of minimum inhibitory concentration (MIC) values and kinetic parameters, showed that KPC-93 exhibited increased resistance to ceftazidime-avibactam, but a drastic decrease in carbapenemase activity. Our data highlight that a KPC variant conferring resistance to ceftazidime-avibactam could be easily induced by ceftazidime-avibactam treatment and that actions are required to control dissemination of these determinants.

IMPORTANCE Ceftazidime-avibactam (CZA) is a novel β-lactam/β-lactamase inhibitor combination with activity against serine β-lactamases, including the Ambler class A enzyme KPC. However, during recent years, there have been increasing reports of emergence of new KPC variants that could confer resistance to CZA. This has limited its clinical application. Here, we reported a new KPC variant, KPC-93, that could confer CZA resistance. KPC-93 possessed a five-amino-acids insertion (Pro-Asn-Asn-Arg-Ala) between Ambler positions 267 and 268 in KPC-2. Our findings have revealed the potential risk of blaKPC gene mutations associated with CZA exposure over a short period of time.

KEYWORDS KPC, ceftazidime-avibactam, Klebsiella pneumoniae

Carbapenem-resistant Enterobacteriaceae (CRE), especially carbapenem-resistant Klebsiella pneumoniae (CRKP), have been highlighted as an urgent threat to global public health by virtue of the high fatality rates and financial burden of infections (1, 2). A retrospective cohort in Brazil showed that the overall 30-day mortality rate of hospitalized adult patients with bloodstream infections (BSI) caused by CRKP was up to 60% (3, 4). The dissemination and circulation of carbapenem resistance in K. pneumoniae strains further complicates clinical practice, leaving few treatment options, such as tigecycline and colistin, which are last-line defenses against CRE infections (5, 6). However, their efficacy has been significantly compromised by their toxicity and the rapid emergence and continuous transmission of tigecycline- and colistin-resistance determinants, such as the plasmid-borne resistance-nodulation-division (RND) efflux pump TmexCD1-ToprJ1, flavin-dependent monooxygenase Tet (X) variants, and movable colistin resistance (mcr) genes (6–9).

Ceftazidime-avibactam (CZA), a novel β-lactam antibiotic-β-lactamase inhibitor combination, has become a potential alternative to tigecycline and colistin against complicated
intra-abdominal urinary tract infections and hospital-acquired pneumonia caused by CRKP strains, especially those producing *Klebsiella pneumoniae* carbapenemase (KPC), the most predominant class A serine β-lactamase conferring carbapenem resistance among *K. pneumoniae* strains globally (10, 11). Avibactam (AVI) is a potent diazabicyclooctenone (DBO) inhibitor of a wide range of β-lactamases, including many class A and C and some class D serine β-lactamases (SBLs) (12). When combined with ceftazidime, AVI protects ceftazidime from degradation by serine β-lactamases through covalent acylation of the SBL active sites (10). Whereas, since the approval of clinical use from FDA in 2015, CZA resistance has been increasingly reported, mainly caused by β-lactamase mutations (13–15). At the same time, according to the NCBI Reference Sequences (RefSeq) database (https://www.ncbi.nlm.nih.gov/pathogens/refgene/#KPC), the number of novel KPC variants has soared unprecedentedly, including many special variants that could confer resistance to enzyme inhibitors, such as KPC-8, -30, -31, -32, -40, -41, -50, -57, -58, -71, -74, and -78. Some KPC variants confer resistance to both inhibitors and extended-spectrum β-lactamases, such as KPC-14, -28, -33, -46, -51, -52, -53, -66, -72, -73, -79, and -82. Such a high number of variants may severely limit anti-infection therapeutic efficacy in clinical settings and pose significant threats to human health.

In this study, we identified a new KPC variant, KPC-93, from two clinical CZA-resistant *K. pneumoniae* strains isolated from a patient after intermittent administration of CZA for about 40 days. Its resistance profiles and mechanisms of resistance were investigated. Our findings have increased the diversity of KPC and shown the treatment dilemma for KPC-producing CRE strains.

**RESULTS**

**Clinical strains and medical history.** In March 2021, a 61-year-old man was admitted to the Second Affiliated Hospital of Zhejiang University with a surgical site infection (SSI) after a lumbar discectomy. The patient experienced recurrent infection during treatment. After administration of CZA for about 25 days (2.5g q8h/d) (Fig. 1), three CRKP strains were isolated from sputum and secretion samples, including two CZA-resistant strains (*K. pneumoniae* 14 and 16) from sputum samples and one CZA-susceptible strain (*K. pneumoniae* 15) from a secretion sample. After 4 weeks of treatment, the patient improved, and all his symptoms resolved. None of the CZA-resistant strains were detected or isolated from his subsequent samples. Broth microdilution susceptibility testing showed that strains *K. pneumoniae* 14, 15, and 16 were resistant to aztreonam, amoxicillin, cefotaxime, ceftazidime, cefmetazole, cefepime, meropenem, ertapenem, piperacillin-tazobactam, cefoperazone/sulbactam, ciprofloxacin, and amikacin, but susceptible to polymyxin B and tigecycline and intermediate to
TABLE 1 MICs of antimicrobial agents for *K. pneumoniae* clinical isolates and *E. coli* TOP10 transformants

| Antimicrobial agent | MIC (µg/mL) | *K. pneumoniae* | E. coli |
|---------------------|-------------|-----------------|--------|
|                     | 14 (KPC-93) | 15 (KPC-2) | 16 (KPC-93) | TOP10 (pTOPO-KPC-2) | TOP10 (pTOPO-KPC-41) | TOP10 (pTOPO-KPC-93) | TOP10 (pTOPO) | ATCC 25922 |
| AMP                 | >128        | >128         | >128       | >128                  | >128                    | >128                    | >0.25          | <0.25       |
| ATM                 | >128        | >128         | >128       | >128                  | >128                    | >128                    | 8              | <0.25       |
| AMX                 | >128        | >128         | >128       | >128                  | >128                    | >128                    | 16             | 8           |
| AMC                 | >128/2      | >128/2       | >128/2     | >128/2                | >128/2                  | >128/2                  | 8              | 8           |
| CTX                 | >128        | >128         | >128       | 16                    | 16                      | 8                       | >0.25          | 0.5         |
| CAZ                 | >128        | >128         | >128       | 32                    | 128                     | 256                     | 1              | <0.25       |
| CZA                 | 64/4        | 1/4          | 32/4       | 0.5/4                 | 16/4                    | 64/4                    | 0.5/4          | <0.25/4     |
| FEP                 | >64         | >64          | >64        | ND*                   | ND                      | ND                      | ND             | ND          |
| CMZ                 | 64          | >128         | 64         | ND                    | ND                      | ND                      | ND             | ND          |
| T2P                 | >256/4      | >256/4       | >256/4     | ND                    | ND                      | ND                      | ND             | ND          |
| SCF                 | 256/128     | 256/128      | 256/128    | ND                    | ND                      | ND                      | ND             | ND          |
| IMP                 | 2           | 16           | 2          | 2                     | 0.125                   | 0.06                    | <0.25          | 0.5         |
| MEM                 | 8           | 128          | 16         | 2                     | 1                       | 0.5                     | <0.25          | 0.5         |
| ETP                 | 32          | >128/32      | 32         | 2                     | 0.25                    | 0.25                    | <0.25          | 0.25        |
| CIP                 | >32         | >32          | >32        | ND                    | ND                      | ND                      | ND             | ND          |
| AK                  | >128        | >128         | >128       | ND                    | ND                      | ND                      | 2              | <0.5        |
| PB                  | 1           | 1            | 1          | ND                    | ND                      | ND                      | <0.5           | ND          |
| TGC                 | 1           | 1            | 1          | ND                    | ND                      | ND                      | ND             | ND          |

*a* Ampicillin; ATM, aztreonam; AMX, amoxicillin; AMC, amoxicillin-clavulanate; CTX, cefotaxime; CAZ, ceftazidime; CZA, ceftazidime-avibactam; FEP, ceftepime; CMZ, cefmetazole; T2P, piperacillin-tazobactam; SCF, cefoperazone/sulbactam; IMP, imipenem; MEM, meropenem; ETP, ertapenem; CIP, ciprofloxacin; AK, amikacin; PB, polymyxin B; TGC, tigecycline.

**ND**, not detected.

imipenem (Table 1). Furthermore, strains *K. pneumoniae* 14 and 16 exhibited increased CZA resistance but decreased carbapenem resistance compared to strain *K. pneumoniae* 15.

**Genomic characterization.** To better understand the genetic environment of this difference, the complete genomes of strains *K. pneumoniae* 14, 15, and 16 were obtained by whole-genome sequencing (Table 2). The genome of strain *K. pneumoniae* 14 was composed of a 5,474,052-bp chromosome and four plasmids with sizes of 197,415, 133,129, 87,095, and 11,970 bp, respectively. The genome of strain *K. pneumoniae* 15 was composed of a 5,477,020-bp chromosome and four plasmids with sizes of 197,415, 133,114, 87,095, and 11,970 bp, respectively. The genome of strain *K. pneumoniae* 16 was composed of a 5,474,051-bp chromosome and four plasmids with sizes of 197,415, 133,129, 87,095, and 11,970 bp, respectively. Pairwise single-nucleotide polymorphism (SNP) analysis for these three strains showed that their core genomes differed only by a few SNPs (*n* = 4). Furthermore, the plasmidomes of these three strains were almost the same, suggesting that these strains might originate from a single clone. These strains were all found to belong to sequence type (ST) 11 based on multi-locus sequence typing (MLST), and to the KL64 and O2v1 serotypes by Kaptive based on capsule and lipid synthesis loci. Analysis of acquired antimicrobial resistance identified 13 antimicrobial-resistance genes encoding resistance to β-lactams, aminoglycosides, fluoroquinolones, tetracyclines, chloramphenicol, sulfonamide, and trimethoprim (Table 2). In addition, *in silico* plasmid replicon typing indicated that these plasmids belonged to the FIβk/HI1B, FI1/R, FI1, and ColRNAI incompatibility groups, respectively (Table 2).

The 197,415-bp IncF1B/H1B, comprising 241 predicted protein-coding genes with a GC content of 50.05%, was identical among these three strains. Being highly similar (100% coverage and 99.99% identity) to plasmids pKP58_1 (GenBank accession no. CP041374.1) and p16ZR-187-IncHI1-197-Vir (GenBank accession no. MN182749.4), this plasmid harbored the virulence genes *iscABCD*, *IsuAT*, *rmpA*, and *rmpA2*, and was designated pKP14_Vir (Table 2, Fig. 2a). Strain *K. pneumoniae* 15 was found to harbor the *blaKPC-2* gene, which was located in a 133,114-bp IncF1/R plasmid with a GC content of 53.34% and comprised of 168 predicted protein-coding genes; this plasmid was designated pKP15_KPC (Table 2, Fig. 2b). The *blaKPC-2* gene was carried on the NTE*KPC*-lb.
The MIC of imipenem against bla to CZA, the DNA fragment encoding blaKPC-93 containing its natural promoter was hydrolysis results indicated that both KPC-2 and KPC-93 can hydrolyze CAZ. The decreased 8-fold compared that against bla compared that against bla K. pneumoniae Strain Plasmid or chromosome Size (bp) Resistance and virulence genes Inc type

### TABLE 2 Genetic characterization of strains K. pneumoniae 14, 15, and 16

| Strain      | Plasmid or chromosome | Size (bp) | Resistance and virulence genes                                                                 | Inc type* |
|-------------|-----------------------|-----------|-------------------------------------------------------------------------------------------------|-----------|
| K. pneumoniae 14 | Chromosome            | 5,474,052 | bla<sub>SHV-182</sub>, adaA2, sul1                                                              | FIBk, HI1B |
|             | pKP14_Vir             | 197,415   | iucABCDIutA, rmpA and rmpA2, iroN, peg344                                                        | FIBk, HI1B |
|             | pKP14_KPC             | 133,129   | bla<sub>CTX-M-65</sub>, bla<sub>TEM-1</sub>, blaKPC-93, bla<sub>SHV-12</sub>, bla<sub>LAP-2</sub>, qnrS1, tet(A), catA2, dfrA14, sul2 | FII, R    |
|             | pKP14_res             | 87,095    |                                                                                                 | FII       |
|             | pKP14_col             | 11,970    |                                                                                                 | CoIRNAI   |
| K. pneumoniae 15 | Chromosome            | 5,477,020 | bla<sub>SHV-182</sub>, adaA2, sul1                                                              | FIBk, HI1B |
|             | pKP15_Vir             | 197,415   | iucABCDIutA, rmpA and rmpA2, iroN, peg344                                                        | FIBk, HI1B |
|             | pKP15_KPC             | 133,114   | bla<sub>CTX-M-65</sub>, bla<sub>TEM-1</sub>, blaKPC-93, bla<sub>SHV-12</sub>, bla<sub>LAP-2</sub>, qnrS1, tet(A), catA2, dfrA14, sul2 | FII, R    |
|             | pKP15_res             | 87,095    |                                                                                                 | FII       |
|             | pKP14_col             | 11,970    |                                                                                                 | CoIRNAI   |
| K. pneumoniae 16 | Chromosome            | 5,474,051 | bla<sub>SHV-182</sub>, adaA2, sul1                                                              | FIBk, HI1B |
|             | pKP16_Vir             | 197,415   | iucABCDIutA, rmpA and rmpA2, iroN, peg344                                                        | FIBk, HI1B |
|             | pKP16_KPC             | 133,129   | bla<sub>CTX-M-65</sub>, bla<sub>TEM-1</sub>, blaKPC-93, bla<sub>SHV-12</sub>, bla<sub>LAP-2</sub>, qnrS1, tet(A), catA2, dfrA14, sul2 | FII, R    |
|             | pKP16_res             | 87,095    |                                                                                                 | FII       |
|             | pKP14_col             | 11,970    |                                                                                                 | CoIRNAI   |

*Inc, incompatibility group.

transposon. Being highly similar (100% coverage and 99.99% identity) to plasmids pKP58_2 (GenBank accession no. CP041375.1) and p16ZKR-17-IncFII-133-CR (GenBank accession no. MN182746.1), this plasmid also harbored the resistance genes bla<sub>CTX-M-65</sub>, bla<sub>TEM-1</sub>, and bla<sub>SHV-12</sub> (Fig. 2b). Strains K. pneumoniae 14 and 16 also harbored this plasmid, but with a 15-bp insertion in bla<sub>KPC-2</sub> gene, which might be the cause of CZA resistance in K. pneumoniae strains 14 and 16 (Fig. 2b).

**Identification of a novel KPC variant.** Sequence analysis indicated that the novel allele possessed a five-amino-acids insertion (Pro-Asn-Asn-Arg-Ala) between Ambler positions 267 and 268 in KPC-2, and it was designated KPC-93 (Fig. 3c). Among these, 22 have been demonstrated to confer CZA resistance, and the key residues known to be implicated in CZA resistance of KPC included positions R164, W165, L169, D179, V240, Y241, G242, T243, P266, D271, and E276 (Fig. 2b). Alignment of all KPC alleles indicated that KPC-29, -34, -41, -44, -58, -67, -73, -76, -79, and -80 showed insertion mutations in this region (Fig. 3c). Among these, KPC-41, -44, and -67 have been demonstrated to confer CZA resistance. (14, 17, 18).

**Characterization of KPC-93.** To confirm whether bla<sub>KPC-93</sub> can mediate resistance to CZA, the DNA fragment encoding bla<sub>KPC-93</sub> containing its natural promoter was amplified, ligated into vector pCR-BluntII-Topo, and transformed to E. coli strain TOP10. Constructs carrying bla<sub>KPC-2</sub> and bla<sub>KPC-41</sub> were also included for comparison. The MIC of CZA against E. coli strain TOP10 carrying bla<sub>KPC-93</sub> was 64/4 μg/mL, a 128-fold increase compared that against bla<sub>KPC-2</sub>. The MIC of imipenem against E. coli strain TOP10 carrying bla<sub>KPC-93</sub> was shown to be decreased 8-fold compared that against bla<sub>KPC-2</sub> and decreased 4-fold compared that against bla<sub>KPC-41</sub> (Table 1). Furthermore, the kinetic constants of KPC-93 and KPC-2 for imipenem, meropenem, and ceftazidime could not be determined. The kinetic constants of KPC-2 and KPC-93 on nitrocefin were determined to be $K_{m} = 17.93$ and 115.9 μM, respectively, and $K_{cat} = 2.197$ and $4.11 \times 10^{-4}$ s$^{-1}$, respectively (Table 3). The hydrolysis results indicated that both KPC-2 and KPC-93 can hydrolyze CAZ. The values of KPC-2 and KPC-93 for CAZ were determined. The IC50 of KPC2 was 45.1 nM and IC50 of KPC93 was 575 nM (Fig. 4).

Structure of KPC-93 was also modeled using structure of KPC-2 in complex with avibactam as the template (PDB ID: 4ZBE) and compared to that of KPC-2. We found three helical regions surrounding the active site of KPC-2 which exhibited confirmations different from those of KPC-93; this may cause conformational changes of KPC-93, leading to its resistance to inhibition by avibactam (Fig. 5).
DISCUSSION

The global dissemination of KPC-producing *K. pneumoniae* (KPC-KP) has made ceftazidime-avibactam one of the few effective treatment alternatives against KPC-KP infections (11). However, sporadic reports of CZA resistance have risen since this novel β-lactam-β-lactamase inhibitor combination entered clinical routines in America in 2015 (15, 16, 19). China also approved its application in clinical routines on 21 May.

FIG 2 Alignment of virulence plasmids (a) and KPC plasmids (b) with similar structures in *K. pneumoniae* strains 14, 15, and 16 using Easyfig. Colored arrows indicate open reading frames and gray shading indicates regions of shared homology among different elements.
FIG 3 (a) Phylogenetic tree of KPC-93 and KPC variants. Blue background denotes CZA resistance. (b) Sequence alignment of KPC variants with insertion mutations at Ambler positions 267 and 268 in KPC-2. Key residues known to be implicated in CZA resistance are indicated by inverted black triangles.
2019 (13, 20). Here, we obtained two CZA-resistant *K. pneumoniae* strains producing KPC-93 carbapenemases with modest carbapenem resistance from sputum samples, and one carbapenem-resistant but CZA-susceptible *K. pneumoniae* strain carrying *bla*<sub>KPC-2</sub> gene from an excretion sample, from the same patient in succession in China. Our data indicated that the novel variant of KPC-2, achieved through passage under the selection pressure of CZA, has contributed to augmented resistance to this antibiotic and reduced carbapenem resistance. This corroborated results from previous research which indicated that mutations in *bla*<sub>KPC</sub> leading to CZA resistance have been linked to reversion to carbapenem susceptibility (15, 20).

There are three principal resistance mechanisms for KPC-KP strains to CZA, as reported, including co-production of metallo-β-lactamases, increased expression of KPC carbapenemases with porin mutations, and amino acid substitutions/deletions/insertions at pivotal loci of KPC carbapenemases, which was the leading cause of CZA resistance in KPC-KP strains worldwide (13, 16, 21). The Ω loop, with amino acid positions from 164<sub>Arg</sub> to 179<sub>Asp</sub> embraces the core of the active site of KPC β-lactamase and is vulnerable to mutations relevant to CZA resistance, especially 169<sub>Leu</sub> and 179<sub>Asp</sub> (15, 20, 22). The number of novel isoforms of KPC carbapenemases has increased rapidly since 2020 (16). So far, 98 mutant alleles of *bla*<sub>KPC</sub> have emerged and 31 of them were classified as “inhibitor-resistant” according to the NCBI reference gene catalog. Most CZA-resistant KPC variant enzymes contained mutations at either of the loci mentioned above; most frequently at D179Y, followed by L169P, D179N, D179A, and L169Q (16, 20, 22–24).

Currently, no concentrated and epidemic CZA resistance mechanisms have been discovered in China in addition to the co-production of metallo-β-lactamases in KPC-KP strains (13). Shen et al. (25) found that increased copy number and gene expression of the wild-type *bla*<sub>KPC-2</sub> combined with OmpK35 deficiency mediated CZA resistance in KPC-KP isolates in Shanghai. Xu et al. (26) reported that a novel *bla*<sub>CXM-172</sub> AmpC β-lactamase was tightly associated with reduced CZA susceptibility in Zhejiang province. Additionally, CZA-resistant KPC-KP strains with KPC-2 variants KPC-33, KPC-51, and KPC-52, have been detected in Shanghai, Beijing, and Henan provinces (16, 20, 27).

In this study, we report the first case of KPC-93 carbapenemase-producing, ST11-type *K. pneumoniae* strains conferring resistance to CZA after exposure to CZA for 39 days and verified the one-way conversion from KPC-2 to KPC-93. It is worth noting that KPC-93 can reverse carbapenem resistance, like other variants. The low MIC values of carbapenems against *K. pneumoniae* harboring KPC-2/KPC-3 variants made them readily neglected, and the undetectable properties of some variants by NG-Test CARBA5 has further limited their early detection. Even more concerning is that the number of KPC variants is growing rapidly. The sum of newly identified KPC variants within the last 2 years has exceeded that of the past 2 decades. Various variants may create a more complex situation for drug applications, leading to higher risks to human health in the future.

In conclusion, because KPC-2-producing *K. pneumoniae* strains are highly prevalent in China and in other countries, it is vital for clinicians to monitor the susceptibility of these strains to CZA and adjust the dosage of CZA and therapeutic regimens to prevent therapy failure and the wide spread of CZA-resistant strains.

**MATERIALS AND METHODS**

**Bacterial isolation and phenotypic characterization.** *K. pneumoniae* strains were isolated from clinical samples in a hospital located in Zhejiang, China in 2021. Strains *K. pneumoniae* 14 and 16 were isolated from sputum samples and strain *K. pneumoniae* 15 was isolated from a wound secretion from the same patient. Antimicrobial susceptibility was determined by the broth microdilution method using custom
plates (DL Biotech, China) following Clinical and Laboratory Standards Institute (CLSI) guidelines (28) with 18 antimicrobial agents, including ampicillin, aztreonam, amoxicillin, amoxicillin-clavulanate, cefotaxime, ceftazidime, ceftazidime-avibactam, cefmetazole, cefepime, imipenem, meropenem, ertapenem, piperacillin-tazobactam, cefoperazone/sulbactam, ciprofloxacin, amikacin, polymyxin B, and tigecycline. All tests were performed in duplicate and each test included three biological replicates. The breakpoint of tigecycline was interpreted according to Food and Drug Administration (FDA) guidelines (susceptible MIC, \( \leq 2 \) mg/L; intermediate MIC, 4 mg/L; resistant MIC, \( \geq 8 \) mg/L). The breakpoint of cefoperazone/sulbactam was interpreted according to the CLSI breakpoint of cefoperazone for Enterobacteriaceae.

**Whole-genome sequencing and bioinformatic analysis.** Genomic DNA was extracted using the PureLink Genomic DNA Minikit (Invitrogen, USA) according to the manufacturer’s instructions and sent to Novogene (China) for whole-genome sequencing using the Illumina NovaSeq 6000 platform. Genomic DNA was also subjected to the long-read Nanopore MinION platform after being treated with a supplementary sequencing kit (Oxford Nanopore Technologies, Oxford, United Kingdom). MinION libraries were prepared

![Image of plates with antibiotics](image_url)

**FIG 4** The hydrolysis and Ki values of KPC-2 and KPC-93 against CAZ. (a) Hydrolysis of KPC-2 against CAZ. (b) Hydrolysis of KPC-93 against CAZ. (c) Ki values of KPC-2. (d) Ki values of KPC-93.
using the SQK-RBK004 nanopore sequencing kit according to the manufacturer’s instructions. The library was then added to a MinION flow cell (R9.4.1) and sequenced. Both short and long reads were de novo hybrid assembled using Unicycler v0.4.8 (29). Assembled genome sequences were annotated with RAST v2.0 (30). MLST was determined by using Kaptive software based on the types of genetic variations in the seven housekeeping genes (31). Virulence genes were identified by searching against the BIGSdb *Klebsiella* genome database (https://biggsdb.pasteur.fr/klebsiella/). The BLASTn command lines, with an 80% coverage and identity cutoff, were used to map genome sequences against antibiotic resistance genes, insertion sequences, and plasmid replicons. The resistance genes and plasmid replicon databases were obtained from the Center for Genomic Epidemiology (http://www.genomicepidemiology.org/). Alignment of plasmids with similar structures was performed using Easyfig, win_2.1 (33).

**KPC variant identification and phylogenetic analysis.** The protein sequences of 98 total KPC variants (KPC-2 to KPC-108) deposited in the NCBI GenBank database were downloaded. The genome sequences of strains *K. pneumoniae* 14, 15, and 16 were subjected to BLAST against all KPC variants, using blastx to identify KPC alleles. The KPC-2 allele was identified in strain *K. pneumoniae* 15, while a novel KPC-2 variant, KPC-93, was identified in strains *K. pneumoniae* 14 and 16. The protein sequences of KPC-93 and other KPC variants were aligned using the program Clustal Omega (34) and the final output was submitted to RAxML for phylogenetic analysis using a maximum-likelihood method (35). The resulted phylogenetic tree was further modified by iTOL (36). The aligned sequences were also subject to analysis by ESPript 3.0.58 (37).

**Cloning, expression, and purification of carbapenemases KPC-2, KPC41, and KPC-93.** The *bla*KPC-2 gene was amplified using the primers KPC2-all-fw and KPC2-all-rev. The PCR product was then ligated into vector pCR-BluntII-Topo (Invitrogen, USA) and the resulting plasmid, pTOPO-KPC-2, was further transformed into *Escherichia coli* strain TOP10. The *bla*KPC-41 and *bla*KPC-93 genes were obtained by site-directed mutagenesis, using the *bla*KPC-2 gene as the template, by the GeneArt Site-Directed Mutagenesis System (Invitrogen, USA) according to the manufacturer’s instructions.

Carbapenemases KPC-2, KPC41, and KPC-93 were purified from *E. coli* TOP10 strains containing plasmids pTOPO-KPC-2, pTOPO-KPC-41, and pTOPO-KPC-93, respectively. Briefly, bacteria were cultured overnight at 37°C in Luria broth with kanamycin (50 μg/mL) and pelleted by centrifuge at 4,500 × g for

![FIG 5](image_url) Structural model of KPC-93 using the crystal structure of KPC-2 complexed with avibactam (PDB ID: 4ZBE) as the template. (a) Modeled structure of KPC-93. (b) Structure of KPC-2. (c) Structure alignment of KPC-93 and KPC-2. Three major different regions were labeled.
30 min. Bacterial cells were then resuspended in 50 mM morpholine ethanesulfonic acid (MES) buffer (pH 5.5) and disrupted by sonication. After centrifuging at 30,000 × g for 1 h, the supematant containing the enzymes was collected. Purification was performed in two steps. First, the supematant was loaded onto a HiTrap Q HP column (GE Healthcare, Germany) which was pre-equilibrated with MES buffer and eluted by continuously increasing salt concentration (NaCl) from 0 to 1 M. Next, the collected fractions containing target proteins were concentrated using Amicon Ultra-15 Centrifugal Filter Units (Millipore, USA) and loaded onto a HILIC 16/600 Superdex 75-pg size exclusion column (GE Healthcare, Germany) which was pre-equilibrated with 100 mM sodium phosphate (pH 7.0). Eluted proteins were concentrated, flash-frozen, and stored at −80°C. Purification was detected by SDS-PAGE.

The hydrolysis of KPC-2 and KPC-93 against CAZ. The hydrolysis of KPC-2 and KPC-93 against CAZ was determined. Briefly, a bacterial culture of a CAZ-susceptible K. pneumonia strain was suspended in saline and inoculated on agar plates containing 1 µg/mL CAZ. Different amounts of purified KPC-2 and KPC-93 proteins were added into the Oxford Cup. Phosphate-buffered saline was used as a negative control. The plates were cultured at 37°C for 16 h and bacterial growth was observed.

Structure modeling of carbapenemase KPC-93. Homology modeling of carbapenemase KPC-93 was performed using a crystal structure of KPC-2 in complex with avibactam as the template (PDB ID: 4ZBE) (38) on the Swiss-Model workspace (39). The models were visualized by PyMol under an academic/nonprofit license.

Data availability. Complete sequences of the chromosomes and plasmids of K. pneumoniae 14, 15, and 16 have been deposited in the GenBank database under accession PRJNA779111. The novel KPC variant KPC-93 sequence has been deposited in the GenBank database under accession number MZ569034.1.

ACKNOWLEDGMENTS

The work was supported by the National Natural Science Foundation of China (no. 81772250) and the International (Regional) Cooperation and Exchange Programs of National Natural Science Foundation of China (no. 81861138052).

We have no conflicts of interest to report. All authors have submitted the ICMJE form for Disclosure of Potential Conflicts of Interest.

REFERENCES

1. Grundmann H, Glasner C, Albigcr B, Aanensen DM, Tomlinson CT, Andrasovic AT, Cantorn R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gnaidkowsk M, Livermore DM, Nordmann P, Poirel L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford N, Monnet DL, European Survey. 2017. Occurrence of carbapenemase-producing Enterobacteriaceae (EsCAPae) Working Group. 2017. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EsCAPae): a prospective, multinational study. Lancet Infect Dis 17:153–163. https://doi.org/10.1016/S1473-3099(16)30257-2.

2. van Duin D, Arias CA, Komarow L, Chen L, Hansom BM, Weston G, Cober E, Chang OB, Jacob JT, Satlin MJ, Fries BC, Garcia-Diaz J, Doi Y, Dhar S, Kage K, Earley M, Hurley KM, Boscovich RN, Shrophshire WC, Dinh A, Manca C, Lutterbach CL, Wang M, Paterson DL, Banerjee R, Patel R, Evans S, Hill C, Arias R, Chambers HF, Fowler VG, Kreiswirth BN, Bonomo RA. 2010. Molecular and clinical epidemiology of carbapenem-resistant Enterobacteriaces in the USA (CRACKLE-2): a prospective cohort study. Lancet Infect Dis 20:731–741. https://doi.org/10.1016/S1473-3099(10)70355-8.

3. Andrei DO, Pereira Dantas P, Martins WBS, Marques De Carvalho F, Almeida LGP, Sands K, Portel E, Safer J, Cavallaro MF, Vasconcelos AL, Medeiros EA, Walsh TR, Gales AC. 2020. An emerging clone, Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae sequence type 16, associated with high mortality rates in a CC238-endemic setting. Clin Infection Dis 71:e141–e150. https://doi.org/10.1093/cid/ciz1095.

4. Taiwa E, Haidich AB, Kokkali S, Arvanitidou M. 2011. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 11:834–844. https://doi.org/10.1016/S1473-3099(11)70777-3.

5. Gu D, Dong N, Zheng Z, Lin D, Huang M, Wang L, Chen EW-C, Shu L, Yu Y, Zhang R, Chen S. 2018. A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study. Lancet Infectious Diseases 18:37–46. https://doi.org/10.1016/S1473-3099(17)30489-9.

6. Poirel L, Jayol A, Nordmann P. 2017. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids and chromosomes. Clin Microbiol Rev 30:557–596. https://doi.org/10.1128/CMR.00064-16.

7. Lv L, Wan M, Wang C, Gao X, Yang Q, Partridge SR, Wang Y, Zong Z, Doi Y, Shen J, Jia P, Song Q, Zhang Q, Yang J, Huang X, Wang M, Liu J-H. 2020. Emergence of a plasmid-encoded resistance-nodulation-division efflux pump conferring resistance to multiple drugs, including tigecycline, in Klebsiella pneumoniae. mBio 11:e02930-19. https://doi.org/10.1128/mBio.02930-19.

8. He T, Wang R, Liu D, Walsh T, Zhang R, Lv Y, Ke Y, Ji Q, Wei R, Liu Z, Shen Y, Wang G, Sun L, Lei L, Lv Z, Li Y, Pang M, Wang L, Sun Q, Fu Y, Song H, Hao Y, Shen Z, Wang S, Chen G, Wu C, Shen J, Wang Y, 2019. Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans. Nat Microbiol 4:1450–1456. https://doi.org/10.1038/s41564-019-0445-2.

9. Li Y-L, Wang Y, Walsh TR, Yi L-X, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu L-F, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu J-H, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16:161–168. https://doi.org/10.1016/S1473-3099(15)00424-7.

10. Tuon F, Rocha J, Formigoni-Pinto M. 2018. Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review. Infec Dis 46:165–181. https://doi.org/10.1053/j.infdis.2017.01.096.

11. Tumbarello M, Ticriachi E, Corona A, De Rosa F, Bassetti M, Mussini C, Menichetti F, Viscoli C, Campoli C, Venditti M, De Gasperi A, Mularoni A, Tascini C, Parruti G, Palletto C, Sica S, Concia E, Culkera R, De Pascale G, Capone A, Antonini S, Cordic S, Righi E, Losito A, Digaeta M, Amadori F, March/April 2022 Volume 10 Issue 2 10.1128/spectrum.02655-21 10.
